283 related articles for article (PubMed ID: 27442600)
1. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
[TBL] [Abstract][Full Text] [Related]
2. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Sivaraj D; Green MM; Kang Y; Long GD; Rizzieri DA; Li Z; Garrett AH; McIntyre JL; Chao NJ; Gasparetto C
Blood Cancer J; 2018 Jul; 8(8):71. PubMed ID: 30065277
[No Abstract] [Full Text] [Related]
7. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Bilotti E; Vesole DH; McBride L; Schmidt L; Gao Z; Gilani M; McNeill A; Bednarz U; Richter J; Mato A; Graef T; Siegel DS
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):558-562. PubMed ID: 27769558
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC
J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Beck J; Schwarzer A; Gläser D; Mügge LO; Uhlig J; Heyn S; Kragl B; Mohren M; Hoffmann FA; Lange T; Schliwa T; Zehrfeld T; Becker C; Kreibich U; Winkelmann C; Edelmann T; Andrea M; Bill M; Jentzsch M; Schwind S; Niederwieser D; Pönisch W
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2545-2553. PubMed ID: 28828689
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2
Mey UJ; Brugger W; Schwarb H; Pederiva S; Schwarzer A; Dechow T; Jehner P; Rauh J; Taverna CJ; Schmid M; Schmidt-Hieber M; Doerfel S; Fischer N; Ruefer A; Ziske C; Knauf W; Cathomas R; von Moos R; Hitz F; Sauter R; Hiendlmeyer E; Cantoni N; Bargetzi M; Driessen C
Br J Haematol; 2017 Mar; 176(5):770-782. PubMed ID: 27983764
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Knop S; Gerecke C; Liebisch P; Topp MS; Platzbecker U; Sezer O; Vollmuth C; Falk K; Glasmacher A; Maeder U; Einsele H; Bargou RC
Blood; 2009 Apr; 113(18):4137-43. PubMed ID: 19182205
[TBL] [Abstract][Full Text] [Related]
15. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
[TBL] [Abstract][Full Text] [Related]
16. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
Dhakal B; D'Souza A; Hamadani M; Arce-Lara C; Schroeder K; Chhabra S; Shah NN; Gauger K; Keaton T; Pasquini M; Hari P
Blood Cancer J; 2019 Jul; 9(8):56. PubMed ID: 31358733
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC; Mazumder A; Vesole DH; Kaufman JL; Colson K; McKenney M; Lunde LE; Feather J; Maglio ME; Warren D; Francis D; Hideshima T; Knight R; Esseltine DL; Mitsiades CS; Weller E; Anderson KC
Blood; 2014 Mar; 123(10):1461-9. PubMed ID: 24429336
[TBL] [Abstract][Full Text] [Related]
20. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Quach H; Fernyhough L; Henderson R; Corbett G; Baker B; Browett P; Blacklock H; Forsyth C; Underhill C; Cannell P; Trotman J; Neylon A; Harrison S; Link E; Swern A; Cowan L; Dimopoulos MA; Miles Prince H
Br J Haematol; 2017 May; 177(3):441-448. PubMed ID: 28197996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]